X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) issued inducement option awards effective January 30, 2026, under its 2019 Inducement Equity Incentive Plan to new employees.

The awards total 20,000 options, each with a ten‑year term and an exercise price of $3.70 (closing price on January 30, 2026). Options vest over four years (25% after 12 months, then monthly over 36 months).

News Market Reaction – XFOR

+0.50%

15 alerts

+0.50% News Effect

+3.6% Peak in 3 hr 57 min

+$2M Valuation Impact

$349M Market Cap

0.7x Rel. Volume

On the day this news was published, XFOR gained 0.50%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.6% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $349M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement options granted: 20,000 shares Option exercise price: $3.70 per share Option term: 10 years +5 more

8 metrics

Inducement options granted 20,000 shares Aggregate options under 2019 Inducement Equity Incentive Plan

Option exercise price $3.70 per share Equal to XFOR closing price on January 30, 2026

Option term 10 years Ten-year term for inducement stock options

Vesting schedule 4 years (25% after 12 months) Remainder vests monthly over following 36 months

Current share price $3.70 Pre-news price context for XFOR

52-week range $1.35–$24.426 XFOR pre-news 52-week low and high

Price vs 52-week high -84.85% Distance from 52-week high before this news

Price vs 52-week low 174.07% Above 52-week low before this news

Market Reality Check

Price: $4.17 Vol: Volume 255,497 is below t...

normal vol

$4.17 Last Close

Volume Volume 255,497 is below the 20-day average of 338,354 (relative volume 0.76x). normal

Technical Shares at $3.70 are trading above the 200-day MA of $3.31.

Peers on Argus

XFOR is modestly higher (+0.27%) while key biotech peers show mixed to negative ...

XFOR is modestly higher (+0.27%) while key biotech peers show mixed to negative moves, including VANI (-6.71%), ACET (-4.99%), and IGMS (-2.31%), indicating a stock-specific reaction to the inducement grant rather than a sector-wide move.

Historical Context

5 past events · Latest: Nov 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 05	Conference participation	Neutral	-10.6%	Participation in Guggenheim healthcare innovation conference with webcast and meetings.
Nov 05	Earnings and update	Positive	-10.6%	Q3 2025 results, major financings, runway to end of 2028, and restructuring.
Oct 27	Offering closing	Negative	-1.6%	Closing of underwritten public offering with full underwriter option exercise.
Oct 24	Offering pricing	Negative	+23.0%	Pricing of $135M underwritten offering of shares and pre-funded warrants.
Oct 23	Offering proposed	Negative	-0.3%	Announcement of proposed underwritten offering to fund Phase 3 mavorixafor.

Pattern Detected

Recent history shows mixed reactions around financing and corporate updates, with some dilutive offerings sold off and one pricing announcement drawing a sharp positive move.

Recent Company History

Over the last few months, X4 has focused on financing and corporate milestones. In late October 2025, it announced and then closed a public offering, including pre-funded warrants, with gross proceeds of about $155.3M, and saw share-price reactions ranging from -1.58% to +22.98%. The Q3 2025 earnings and conference participation on November 5, 2025 coincided with a -10.58% move. Against this backdrop, the current, relatively small employee inducement option grant fits into ongoing use of equity-based compensation but without the scale of prior financings.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-09-10

X4 has an active Form S-3 shelf filed on 2025-09-10, primarily registering resale of shares held by selling stockholders rather than a new primary raise. The shelf cites an April 29, 2024 FDA approval for XOLREMDI and includes an auditor going-concern explanatory paragraph. It has been used at least 2 times via 424B5 filings dated 2025-10-23 and 2025-10-24.

Market Pulse Summary

This announcement outlines a standard inducement grant of stock options for new hires, covering 20,0...

Analysis

This announcement outlines a standard inducement grant of stock options for new hires, covering 20,000 shares at an exercise price of $3.70 with a four-year vesting schedule. It follows a period characterized by sizeable financings and an active Form S-3 used via 424B5 offerings. Investors monitoring X4 may focus more on future clinical, commercial, and financing updates than on this routine compensation action when assessing the company’s trajectory.

Key Terms

nasdaq listing rule 5635(c)(4), inducement awards, equity incentive plan, exercise price, +2 more

6 terms

nasdaq listing rule 5635(c)(4) regulatory

"These stock awards were granted as an inducement ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement awards financial

"the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan"

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

equity incentive plan financial

"under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

exercise price financial

"The options have a ten-year term and an exercise price of $3.70 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"Each option will vest over a four-year period, with 25% of the shares vesting after 12 months"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

award agreement financial

"The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement"

An award agreement is a legal contract that spells out the terms of a pay or equity grant—such as stock options, restricted shares, or cash bonuses—given to an employee, director or consultant. It describes what is being granted, any conditions for keeping it (for example, earning it over time or meeting performance targets), and what happens if the person leaves or breaks rules. Investors care because these agreements affect company costs, potential share dilution and how executives are motivated and rewarded.

AI-generated analysis. Not financial advice.

BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 30, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 20,000 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.

The options have a ten-year term and an exercise price of $3.70 per share, which is equal to the closing price of X4’s common stock on January 30, 2026. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in patients with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

X4 Investor Contact:
IR@X4pharma.com 

FAQ

What did X4 Pharmaceuticals (XFOR) announce on February 2, 2026 regarding inducement grants?

X4 announced the grant of options to purchase 20,000 shares to new employees under its 2019 Inducement Plan. According to the company, the awards were made effective January 30, 2026 and approved by the compensation committee in compliance with Nasdaq rules.

How many shares and what exercise price were set for the XFOR inducement options?

The company granted options covering an aggregate of 20,000 shares with an exercise price of $3.70 per share. According to the company, $3.70 equals X4's closing stock price on January 30, 2026 and is the set strike for these options.

What are the term and vesting terms for the XFOR inducement option awards?

Each option has a ten‑year term and vests over four years with standard 25% after 12 months, then monthly over 36 months. According to the company, vesting is subject to continued employment on each vesting date.

Why were inducement awards issued under Nasdaq Listing Rule 5635(c)(4) for XFOR?

The awards were issued as inducements to newly hired employees in reliance on Nasdaq Listing Rule 5635(c)(4). According to the company, the 2019 Inducement Plan is used exclusively for grants to individuals not previously employed by X4.

What shareholder impact could XFOR inducement options have if exercised?

If fully exercised, the options would result in issuance of 20,000 common shares, creating potential dilution equal to those shares. According to the company, actual shareholder impact depends on total outstanding shares and whether and when the options are exercised.